Zoryve™ (roflumilast – Arcutis Biotherapeutics) has obtained FDA approval as a topical treatment for plaque psoriasis, including for intertriginous areas (skin folds), in patients who are at least 12 years old.

• Under the recommended dosing, Zoryve is applied once daily to affected areas of the skin.
• Arcutis Biotherapeutics has launched Zoryve at a wholesale acquisition cost (WAC) of $825 per 60g tube.